dc.contributor.author |
Krebs, J |
en |
dc.contributor.author |
Coppell, KJ |
en |
dc.contributor.author |
Cresswell, P |
en |
dc.contributor.author |
Downie, M |
en |
dc.contributor.author |
Drury, P |
en |
dc.contributor.author |
Gregory, A |
en |
dc.contributor.author |
Kenealy, Timothy |
en |
dc.contributor.author |
McNamara, C |
en |
dc.contributor.author |
Miller, SC |
en |
dc.contributor.author |
Smallman, K |
en |
dc.date.accessioned |
2017-11-26T21:02:55Z |
en |
dc.date.issued |
2016-06-10 |
en |
dc.identifier.citation |
New Zealand Medical Journal 129(1436):6-9 10 Jun 2016 |
en |
dc.identifier.issn |
0028-8446 |
en |
dc.identifier.uri |
http://hdl.handle.net/2292/36552 |
en |
dc.description.abstract |
New Zealand is well behind the rest of the developed world in access to funded drugs for managing type 2 diabetes. Over the last 12 years three new classes of glucose-lowering drugs have come through clinical trials to market. The principal strengths of all three novel classes of medicine are their lack of hypoglycaemia (low blood sugar), their frequent acceptability in patients intolerant of or contraindicated for existing funded drugs, and avoidance of weight gain. International guidelines focus on individualization of treatment and avoidance of hypoglycaemia. This is extremely difficult for New Zealanders with type 2 diabetes when we do not have access to modern drug treatments. |
en |
dc.format.medium |
Electronic |
en |
dc.language |
eng |
en |
dc.publisher |
New Zealand Medical Association |
en |
dc.relation.ispartofseries |
New Zealand Medical Journal |
en |
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. |
en |
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
en |
dc.subject |
Humans |
en |
dc.subject |
Diabetes Mellitus, Type 2 |
en |
dc.subject |
Hypoglycemia |
en |
dc.subject |
Hemoglobin A, Glycosylated |
en |
dc.subject |
Hypoglycemic Agents |
en |
dc.subject |
Drug Costs |
en |
dc.subject |
Financing, Government |
en |
dc.subject |
Health Services Accessibility |
en |
dc.subject |
New Zealand |
en |
dc.subject |
Sodium-Glucose Transporter 2 |
en |
dc.subject |
Glucagon-Like Peptide 1 |
en |
dc.subject |
Practice Guidelines as Topic |
en |
dc.subject |
Dipeptidyl-Peptidase IV Inhibitors |
en |
dc.subject |
Healthcare Financing |
en |
dc.title |
Access to diabetes drugs in New Zealand is inadequate |
en |
dc.type |
Journal Article |
en |
pubs.issue |
1436 |
en |
pubs.begin-page |
6 |
en |
pubs.volume |
129 |
en |
dc.description.version |
VoR - Version of Record |
en |
dc.rights.holder |
Copyright: New Zealand Medical Association |
en |
dc.identifier.pmid |
27355224 |
en |
pubs.end-page |
9 |
en |
pubs.publication-status |
Published |
en |
dc.rights.accessrights |
http://purl.org/eprint/accessRights/OpenAccess |
en |
pubs.subtype |
Editorial Comment |
en |
pubs.elements-id |
603766 |
en |
pubs.org-id |
Medical and Health Sciences |
en |
pubs.org-id |
School of Medicine |
en |
pubs.org-id |
Medicine Department |
en |
dc.identifier.eissn |
1175-8716 |
en |
pubs.record-created-at-source-date |
2017-11-27 |
en |
pubs.dimensions-id |
27355224 |
en |